Theragene Pharmaceuticals
Latest round
- Series A
Last raised
- Dec 2017
Total raised
- $0.2M
Investors
- 2
About Theragene Pharmaceuticals
Theragene Pharmaceuticals, Inc.Founded in 2011 and headquartered in San Diego, California, Theragene Pharmaceuticals specializes in immunotherapy and gene therapy.20 mn from Thynk Capital.Theragene Pharmaceuticals specializes in advanced immunotherapy and gene therapy solutions, primarily targeting cancer and cardiovascular diseases. The company's core offerings include immunotherapy technologies that enhance the immune system's capacity to identify and combat tumor cells, providing patients with a safer alternative to conventional treatments. Additionally, their gene therapy platform employs Adeno-Associated Virus (AAV) technology, which is aimed at addressing various cardiovascular conditions. These therapies represent significant advancements in treatment modalities, developed with the goal of improving patient outcomes.Theragene Pharmaceuticals generates revenue through strategic partnerships and collaborations aimed at developing and commercializing its therapeutic products. The company engages in B2B transactions with healthcare providers, research institutions, and pharmaceutical companies, facilitating the delivery of its immunotherapy and gene therapy solutions. Revenue streams are established through licensing agreements and collaborative development deals, which allow clients to access Theragene's proprietary technologies. Specific pricing structures for the company’s flagship products are set in accordance with the nature of the partnership or agreement, reflecting the therapeutic value and the innovative nature of the treatments offered.Theragene Pharmaceuticals is focusing on the development of new products in immunotherapy and gene therapy, with plans to expand its offerings to address additional cancer types and cardiovascular conditions by 2025. The company aims to penetrate new markets in Europe and Asia, targeting healthcare providers and research institutions by the end of 2025.
Who invested in Theragene Pharmaceuticals
2 investors across 2 rounds
See all investors in Theragene Pharmaceuticals
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Theragene Pharmaceuticals
Who invested in Theragene Pharmaceuticals?
Theragene Pharmaceuticals has 2 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Theragene Pharmaceuticals raised?
Theragene Pharmaceuticals has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Theragene Pharmaceuticals last raise money?
Theragene Pharmaceuticals's most recent round on record is a Series A, in Dec 2017.
What does Theragene Pharmaceuticals do?
Theragene Pharmaceuticals, Inc.
Where is Theragene Pharmaceuticals headquartered?
Theragene Pharmaceuticals is headquartered in San Diego, US.
Which VCs invest in companies like Theragene Pharmaceuticals?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Theragene Pharmaceuticals's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Theragene Pharmaceuticals? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.